{"id":"NCT03257813","sponsor":"Laboratorios Sophia S.A de C.V.","briefTitle":"Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)","officialTitle":"Clinical Study to Evaluate the Non-inferiority of PRO-122 an Ophthlamic Solution Manufactured by Laboratorios Sophia, Previous Treatment With Krytantek Ofteno ®, in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04-01","primaryCompletion":"2017-03-01","completion":"2017-06-18","firstPosted":"2017-08-22","resultsPosted":"2019-12-09","lastUpdate":"2019-12-09"},"enrollment":60,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Primary Open Angle Glaucoma","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"PRO-122","otherNames":["timolol, dorzolamide, brimonidine"]},{"type":"DRUG","name":"Krytantek Ofteno®","otherNames":["timolol, dorzolamide, brimonidine"]}],"arms":[{"label":"Group A","type":"OTHER"},{"label":"Group B","type":"OTHER"}],"summary":"Aim: To demonstrate the non-inferiority of the PRO-122 ophthalmic solution manufactured by Laboratorios Sophia S.A. de C.V. versus Krytantek Ofteno® ophthalmic solution like hypotensive therapy in subjects with primary open angle glaucoma or ocular hypertension.\n\nStudy design: a multicentric, prospective, crossover (2x2), double blind clinical study. Sample size: one hundred patients with primary open angle glaucoma or ocular hypertension. Patients in the period 1: In the first sequence 30 patients will be assigned to receive the ophthalmic solution: Krytantek Ofteno ® (timolol 0.5%%/brimonidine 0.2%/dorzolamide 2%) 1 drop B.I.D. during 30 days and the second sequence 30 patients will be assigned to receive the ophthalmic solution: PRO-122 1 drop B.I.D. during 30 days in the same period. Washout period: 20 hours. Patients in the period 2: the pharmacological intervention change to the opposite therapy for 30 days","primaryOutcome":{"measure":"Intraocular Pressure (IOP)","timeFrame":"Change from Baseline intraocular pressure at day 30 and 60.","effectByArm":[{"arm":"Sequence A","deltaMin":13.6,"sd":2.9},{"arm":"Sequence B","deltaMin":12.13,"sd":1.8}],"pValues":[{"comp":"OG000","p":"0.013"},{"comp":"OG001","p":"0.001"},{"comp":"OG000 vs OG001","p":"0.050"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["29680880"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":60},"commonTop":["rhinopharyngitis","pharyngitis tonsillitis","Dotted Keratopathy","headache","allergic Blepharokeratoconjunctivitis"]}}